The Rising Influence of Rising Affluence

[DewDiligence]

ABT 4Q21 Results by Business Segment

  
                  %Corp      YoY Growth    
 Segment          Sales   (const currency)   
 Medical devices*  33%       +16%     
 Diagnostics       39%        +3%     
 Nutrition         18%        +6%     
 Drugs†            10%        +6% 

4Q21 COVID diagnostics sales were $2.3B, 51% of total 4Q21 diagnostics sales and 20% of total 4Q21 corporate sales.

58% of overall corporate sales were ex-US.

*Includes diabetes care.
†Branded generics in emerging markets.